Artificial Intelligence

With its AI & Autonomy Day, Rivian is betting its future on software. Investors are watching to see if its tech can deliver a true competitive edge.

Imviva Biotech's 'ready-to-use' CAR-T therapy shows breakthrough results, offering new hope and eliminating life-threatening waits for leukemia patients.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

WEP's deployment of 700 inspection systems in Missouri showcases its execution, but can it leverage this win in a competitive multi-billion dollar market?

Wrapbook's acquisition of scheduling platform Cinapse promises to end decades of fragmented workflows, creating a single system for planning and payroll.

An unsolicited bid from Paramount Skydance challenges Netflix's deal for WBD, sparking a high-stakes war for Hollywood's most iconic content library.

A new Canada-Germany digital alliance promises AI and quantum breakthroughs. But can this pact move from policy to patients and transform Canadian health?

A nonprofit's anniversary reveals a powerful brand strategy: using data and free software to find families for 13,000+ children lost in the system.

Nokia is doubling down on open networking with SONiC, a strategic move to challenge proprietary giants and carve out a crucial role in AI infrastructure.

Progressive's massive dividend signals immense financial strength, but what does this capital return strategy mean for its innovation and digital future?

A strategic investment in cybersecurity firm ShorePoint reveals how private capital is becoming a critical force multiplier in securing federal agencies.

Nova Era Labs promises to revolutionize AI education with virtual labs. But in a market of giants, can it deliver on its bold claims of workforce readiness?